Scientific Advisory Board
Harvey F. Lodish, Ph.D., Member, Whitehead Institute for Biomedical Research; Professor of Biology and Professor of Bioengineering, Massachusetts Institute of Technology
James Barry, Ph.D., Executive Vice President and COO, Arsenal Medical
Kevin J. Bitterman, Ph.D., Principal, Polaris Venture Partners
Dalia Cohen, Ph.D., Chief Scientific Officer, ALN Associates
James J. Collins, Ph.D., Professor of Biomedical Engineering, Boston University
John M. Collins, Ph.D., Chief Operating Officer, Center for Integration of Medicine & Innovative Technology (CIMIT)
T. (Teo) Forcht Dagi, M.D., Partner, HLM Venture Partners
Robert D'Amato, M.D., Ph.D., Judah Folkman Chair in Surgery, and Director, Center for Macular Degeneration Research, Children's Hospital Boston
Jonathan Fleming, M.P.A., Managing General Partner, Oxford Bioscience Partners
Rainer Fuchs, Ph.D., Chief Information Officer, Harvard Medical School
Glenn R. Gaudette, Ph.D., Associate Professor, Biomedical Engineering, Worcester Polytechnic Institute
José-Carlos Gutiérrez-Ramos, Ph.D., Senior Vice President, head of BioTherapeutics Research & Development, Pfizer Inc
Henry Kay, U.S. Partner, Medica Venture Partners
Dale Larson, Director of Biomedical Systems, Draper Laboratory
Judith Lieberman, Ph.D., M.D., Senior Investigator, Immune Disease Institute, Children's Hospital Boston and Professor of Pediatrics, Harvard Medical School
Lita L. Nelsen, Director, Technology Licensing Office, Massachusetts Institute of Technology
Barbara Osborne, Professor of Veterinary and Animal Sciences, University of Massachusetts Amherst
Carmichael Roberts, Ph.D., Partner, North Bridge Venture Partners
Lauren Silverman, Ph.D., Managing Director, Novartis Option Fund
Alan E. Smith, Ph.D., Former Chief Scientific Officer, Genzyme Corp.
Alison Taunton-Rigby, Ph.D., Co-Founder, Chief Executive Officer and Director, RiboNovix, Inc.
Guillermo Tearney, M.D., Ph.D., Professor of Pathology, Harvard Medical School
David Walt, Ph.D., Robinson Professor of Chemistry, and Howard Hughes Medical Institute Professor, Tufts University
Phillip Zamore, Ph.D., Professor, Biochemistry and Molecular Pharmacology, University of Massachusetts Medical School
A leader in the field of membrane biology, Harvey F. Lodish has isolated and cloned numerous proteins that reside on the surface of cells and play a role in cell growth, glucose transport, and fatty acid transport. His results have important implications for the treatment of cancer, diabetes, heart disease, and obesity. A Founding Member of the Whitehead Institute, Lodish joined the MIT faculty in 1968 and has been a professor of biology since 1976 and professor of bioengineering since 1999. He earned his PhD at Rockefeller University in 1966. He was elected a fellow of the American Association for the Advancement of Science in 1986, a member of the National Academy of Sciences in 1987, and a fellow of the American Academy of Arts and Sciences in 1999.
James J. Barry, Ph.D., is executive vice president and chief operating officer of Arsenal Medical. Prior to Arsenal Medical, Dr. Barry held a variety of senior positions at Boston Scientific, most recently senior vice president of Corporate Technology Development where he oversaw corporate R&D and preclinical science. While at Boston Scientific, Dr. Barry initiated and led the company’s drug-eluting stent programs. Under Dr. Barry’s leadership, the TAXUS™ drug-eluting coronary stent was developed and became the most successful medical device ever launched, attaining annual sales exceeding $3 billion. Prior to joining Boston Scientific, Dr. Barry held positions at Howmedica and Kontron Instruments. Dr. Barry is the author of multiple articles in peer reviewed publications and holds more than 35 U.S. patents. He currently serves on the advisory boards of the University of Massachusetts-Lowell College of Sciences and Yale University’s College of Biomedical Engineering. Dr. Barry holds a doctorate in biochemistry from the University of Massachusetts-Lowell and a Bachelor of Arts in chemistry from Saint Anselm College.
Kevin J. Bitterman is a Principal at Polaris Venture Partners. Kevin joined Polaris in 2004 and focuses on investments in the life sciences. Prior to joining Polaris, Kevin completed his Ph.D. in genetics at Harvard Medical School. His doctoral research focused on the molecular regulation of caloric restriction and on modulation of a novel class of protein deacetylases. Kevin is a cofounder of Genocea Biosciences and Sirtris Pharmaceuticals (GSK) and was the founding CEO at Visterra Inc. (formerly Parasol Therapeutics).
Kevin currently represents Polaris as a Director of Direct Vet Marketing, Follica Inc., Genocea Biosciences, InSeal Medical, Kala Pharmaceuticals, Neuronetics, Inc., Visterra Inc., and Taris Biomedical. Additionally, Kevin is a Board Observer to Pulmatrix Inc.
Dr. Cohen is Chief Scientific Officer at Asterand, Inc. and worked for many years at Novartis where, among other positions, she was Vice President-Global Head of Functional Genomics, Novartis Institute for Biomedical Research. She also served as Chief Scientific Officer at Rosetta Genomics. Cohen received her B.Sc. In Biology, M.Sc. in Virology and Ph.D. in Cell Biology from the Technion, Israel Institution of Technology and completed her postdoctoral at Albert Einstein College of Medicine.
James J. Collins is a Professor of Biomedical Engineering at Boston University. He is one of the founders of the emerging field of synthetic biology, and a pioneering researcher in systems biology, stochastic resonance, biological dynamics and neurostimulation. Collins has invented a number of novel devices and techniques, including vibrating insoles for enhancing balance, bistable genetic toggle switches for biotechnology and bioenergy applications, and systems biology techniques for identifying drug targets and disease mediators.
Dr. Collins has co-founded two companies based on his technologies: Afferent Corporation, a medical device company, and Cellicon Biotechnologies, a drug discovery company. Dr. Collins is also a member of the Scientific Advisory Board (SAB) of Codon Devices, Inc., and has served on the SAB of Mannkind Corporation (Nasdaq: MNKD) and Bios Group Inc.
Collins' has received numerous awards including the 2007 NIH Director's Pioneer Award and the Ellison Medical Foundation Senior Scholar Award in Aging. From 1987 to 1990, he was a Rhodes Scholar, since which he has been a faculty member in the Department of Biomedical Engineering at Boston University and currently serves as Co-Director of the Center for BioDynamics at Boston University, in addition to performing his duties as a professor.
John M. Collins, PhD, is the COO of CIMIT – Center for Integration of Medicine & Innovative Technology. Before coming to CIMIT, he was president of TIAX LLC, the technology processing company. He has more than 25 years of hands-on, international experience operating at the junction of technology and business, accelerating the development of new technologies and commercialization of innovative products and services, including several years as president of TIAX LLC. Dr. Collins received his BS in mechanical engineering from Rensslaer Polytechnic Institute and his MS and PhD in mechanical engineering from MIT with a concentration in bio-fluids, fluid mechanics and heat/mass transfer. He holds more than 20 US patents on new products and manufacturing processes, including trocars and staplers for MIS, blood fluid warmers, and tendon and ligament repair methods.
Dr. Forcht Dagi is a Partner at HLM Venture Partners. He received an AB from Columbia College, an MD and MPH from Johns Hopkins, an MTS from Harvard, where he was a Joseph P. Kennedy, Jr. Fellow, an MBA with distinction from the Wharton School, and a DMedSc from Queen’s University Belfast. He trained in neurosurgery at the Massachusetts General Hospital and is a diplomat of the American Board of Neurological Surgeons. He is Chairman of the IAP, Distinguished Scholar and Professor at the Medical School of Queen’s University, and Visiting Professor at Harvard Medical School.
Robert D'Amato received his B.A, M.D. and Ph.D. from Johns Hopkins University. He completed his Ophthalmology residency at the Massachusetts Eye and Ear Infirmary. After this training, he undertook a postdoctoral research fellowship in the Folkman laboratories. He has been an independent investigator at Children's since 1994 and is a Professor of Ophthalmology at Harvard Medical School. He currently holds the Judah Folkman Chair in Surgery and leads the endowed Karp Laboratory for Macular Degeneration Research. Noteworthy past research includes the discovery that thalidomide is an angiogenesis inhibitor, which is now FDA approved for cancer. Additional his lab discovered a major role of genetics in determining an individual's angiogenic responsiveness. Further elucidation of these genetic influences may help us predict and potentially regulate our susceptibility to angiogenesis dependent diseases such as cancer and age related macular degeneration.
Jonathan Fleming is the Managing General Partner of Oxford Bioscience Partners, an international venture capital firm specializing in life science technology based investments, with offices in Boston and Connecticut.
Mr. Fleming has been in the investment business for over twenty years, starting and financing growth companies in the United States, Europe and Israel. Prior to joining OBP in 1996, he was a Founding General Partner of MVP Ventures in Boston, MA. He began his investment career with TVM Techno Venture Management in Munich, Germany. Mr. Fleming has also co-founded Medica Venture Partners, a venture capital investment firm specializing in early stage healthcare and biotechnology companies in Israel. Mr. Fleming holds a Master's degree in Public Administration from Princeton University and a Bachelor of Arts degree from the University of California, Berkeley.
Mr. Fleming is on the board of Asterand plc (LSE: ATD). He is also a director of several private companies including Leerink Swann, a Boston based investment bank specializing in healthcare companies. Mr. Fleming is a Trustee of the Museum of Science in Boston and a Senior Lecturer at the MIT Sloan School of Business.
Dr. Rainer Fuchs is the Chief Information Officer at Harvard Medical School. He was previously the Vice President of R&D Information Technology for Cambridge, MA-based Biogen Idec. He also held the positions of Executive Director of BI3, the Biogen Idec Innovation Incubator, which he launched in 2007, and Chairman of the Board of two BI3 portfolio companies, Provasculon and Escoublac. Dr. Fuchs was with Biogen Idec from 2000 until 2012 in various executive leadership roles, including co-head of Discovery Research and VP Informatics and Operations. His experience in the biopharmaceutical industry includes senior leadership positions in life science informatics at Aventis, Ariad, and Glaxo Wellcome.
Glenn R. Gaudette, Ph.D., is an Associate Professor of Biomedical Engineering at Worcester Polytechnic Institute. His research aims to develop a treatment for the millions of Americans suffering from myocardial infarction and other cardiovascular diseases. He is focused on regenerating mechanical and electrophysiological function in the heart. Dr. Gaudette has over 20 years experience in the cardiac research field, including over 10 years in cardiac surgery research. He has over 50 peer reviewed publications, several book chapters and recently edited a book on cardiac regeneration. In May of 2012, he co-founded a company based on some of the pioneering technology developed in his laboratory. Dr. Gaudette won the 2012 Massachusetts Life Science Innovation Day competition and his work has been featured in many different media outlets. He currently teaches biomedical engineering design, biomechanics and physiology. His research has been supported by government (National Institutes of Health; National Science Foundation), non-profit (American Heart Association) and industrial partners.
José-Carlos Gutiérrez-Ramos, Ph.D. is Senior Vice President of Worldwide Biotherapeutics Research and Development at Pfizer and an expert in Immunology and Cell Biology. Before joining Pfizer Dr. Gutiérrez-Ramos was Senior Vice President and Head of the Immuno-Inflammation Centre of Excellence for Drug Discovery at GlaxoSmithKline. He has also served as Senior Vice President of Research and Non-Clinical Development and Chief Scientific Officer at Avidia and was a Senior Scientist and Head of Experimental Therapeutics at Millenium Pharmaceuticals. Dr. Gutiérrez-Ramos has PhD's from both the Basel Institute for Immunology and by the Autonoma University of Madrid, Spain.
Henry Kay is the U.S. Partner of Medica Venture Partners, a healthcare dedicated VC based in Israel and is an active member of two Angel Investing Groups (Boston Harbor Angels and Launchpad).
He retired from Boston Scientific in 2006, where he was Group Vice President of New Market Development / Strategic Planning, Endosurgery Boston Scientific Corporation (BSC). Prior to joining BSC, Henry was based in the UK for five years as Senior Vice President, Sales and Marketing for Allergan Europe, a global eye care company
He has 35 years of experience in the medical industry in roles which include R&D, International Marketing, Regulatory Affairs, and Strategic Planning for major pharmaceutical companies, including Schering-Plough, American Home Products, Sterling Drug and Allergan.
Henry is a fellow of the Royal Society of Medicine (UK). He serves on the Boards of several start up health care companies, including Smart Cells (sold to Merck in 2010), Cool Systems, Avaxia, Wadsworth Medical, and Cannuflow. He was a member of the board of Directors of Microfluidics, a public company in the equipment space for pharmaceutical manufacture (sold to IDEX in 2010). Internationally, he serves on the boards of 2 Canadian Medical Device companies (Cellaegis Devices, Toronto and Dartmouth Medical Research laboratories, Halifax). He has been a mentor with the Venture Mentoring Service of MIT. He serves on the Board of Overseers of Beth Israel-Deaconess and Newton Wellesley Hospitals. In addition, he is serving on the boards of Neurofibromatosis (NF Inc.), Mayyim Hayyim and JF&CS, all non profit organizations.
Henry holds Bachelors (Augusta College) and Master’s Degrees in Chemistry from Rutgers University, and an MBA in International Marketing from Seton Hall University. Henry is a past President of Temple Beth Elohim in Wellesley, Massachusetts. Henry and his wife Laurie have one grown daughter and reside in Weston, Massachusetts.
Mr. Larson is responsible for setting the research agenda and conducts his own work in the area of Nanohole array sensing and laboratory automation. Before joining Draper in February of 2008 Dale was the founding Director of the Technology and Engineering Center at Harvard Medical School where the Nanohole array sensing and automation work was initiated. Mr. Larson has over 28 years of experience in the development of analytical and clinical instrumentation in both academia and in industry. He is an industry veteran of the medical diagnostics industry and was also the President and COO of Genomics Collaborative following a lengthy medical product development consulting career at Arthur D. Little. Mr. Larson received his B.S. from the University of Virginia in 1980 and his M.S. from Stanford University in 1981.
Judy Lieberman is Chair in Cellular and Molecular Medicine in the Program in Cellular and Molecular Medicine at Boston Children’s Hospital and Professor of Pediatrics at Harvard Medical School. She earned a Ph.D. in physics from Rockefeller University and was a physicist at the Institute for Advanced Study in Princeton before earning an M.D. from Harvard and MIT. She trained in internal medicine and hematology-oncology at Tufts Medical Center and was a postdoctoral fellow in immunology at MIT. She does research on how cytotoxic T cells destroy cells marked for immune elimination, HIV immunology, and how microRNAs regulate cell differentiation and cancer. She was the first to show that RNA interference could be harnessed to treat disease in an animal and is actively developing RNAi-based therapeutics for viral infection and cancer. She is a member of the American Academy of Arts and Sciences.
Lita Nelsen is the Director of the Technology Licensing Office at the Massachusetts Institute of Technology, where she has been since 1986. She began her tenure at the MIT TLO specializing in biotechnology and has helped begin many of the biotechnology companies in Massachusetts. Previously, Ms. Nelsen spent 20 years in industry at such companies as Amicon, Millipore, Arthur D. Little, Inc., and Applied Biotechnology. She currently serves on the Board of the Massachusetts Technology Development Corporation and the Mount Auburn Hospital. She is a founder of Praxis, Ltd., a non-profit company for training technology transfer professionals, for which she was awarded an MBE. She is a former president of the Association of University Technology and is an advisor to a number of international organizations concerned with the intellectual property and the development of medicines for neglected tropical diseases.
Since coming to UMass Amherst in 1985, Professor of Veterinary and Animal Sciences Barbara Osborne, a renowned immunologist, has followed her research through a number of twists and turns. In the 19990s, Osborne earned international renown as a researcher of apoptosis, or programmed cell death. Hematech, a start-up Osborne co-founded in 1999, pioneered the use of cloned animals for the development and production of antibodies for therapeutic uses. Now, with support from a 2011 UMass Presidentís Science and Technology Initiatives Fund, Osborne is working with Grew Tew and Maria Santore of the Department of Polymer Science and Engineering to open the groundbreaking Center for Soft Materials Immunology, where UMass faculty and collaborators are developing biologically compatible synthetic materials that allow the bodyís own cellular mechanisms and pathways to control the immune system in order to fight disease. Osborne holds a Ph.D. from Stanford University and performed postdoctoral training at the National Institutes of Health. She has also co-authored Immunology, a leading textbook in the subject.
Dr. Roberts is a Partner of North Bridge Venture Partners. He received his BS and Ph.D. in organic chemistry from Duke University and completed his postdoctoral National Science Foundation fellowship at Harvard University. Roberts also has an MBA from the MIT Sloan School of Management. He serves as an advisor for MIT’s Deshpande Center for Technological Innovation, Harvard’s Nanoscale Science and Engineering Center, and schools of Science and Engineering at Duke University.
Dr. Lauren Silverman is a Managing Director of the Novartis Option Fund in Cambridge, MA, USA.
Prior to joining the Option Fund she was Global Head of Oncology Research Operations for Novartis. Previously, Lauren spent much of her career in Licensing & Business Development, first at OSI Pharmaceuticals and later at Pfizer with responsibilities in the areas of CNS, ophthalmology and oncology. Lauren was also a Director of Strategic Alliances and Head of Cell Biology where she led multiple research teams after having been a founding scientist of Cadus Pharmaceuticals. Lauren was a postdoctoral fellow at Memorial Sloan Kettering Cancer Center and Princeton University and earned her Ph.D. in molecular biology from the University of Utah.
She serves on the Business Advisory Board of the Epilepsy Research Foundation’s Epilepsy Therapy Project, National Cancer Institute’s SBIR review panel, Mass Life Sciences Center Scientific Advisory Board and Board of Directors of Science Club for Girls. Lauren currently serves on the Boards of Directors of the Novartis Venture Funds portfolio companies: Anchor Therapeutics, Ra Pharmaceuticals, Inc., Proteostasis Therapeutics, Pulmatrix Inc., Viamet Pharmaceuticals, Inc., and Celladon Corporation.
Alan E. Smith was the Chief Scientific Officer of Genzyme Molecular Oncology, Genzyme Corp. and Genzyme Biosurgery from September 1996 until 2011. Dr. Smith had also been Senior Vice President of Research of Genzyme Molecular Oncology, Genzyme Corp., and Genzyme Biosurgery since August 1989.
Prior to joining Genzyme, Dr. Smith served as Vice President and Scientific Director of Integrated Genetics, Inc., from November 1984 to its acquisition by Genzyme in August 1989. From October 1980 to October 1984, Dr. Smith served as Head of The Biochemistry Division of the National Institute for Medical Research, Mill Hill, London, England and from 1972 to October 1980, he served as Member of the scientific staff for The Imperial Cancer Research Fund in London, England.
Alison Taunton-Rigby has more than 30 years of experience in the biomedical and pharmaceutical sectors. As an industry leader in the life science and healthcare sectors she has achieved results in developing products and building companies. Dr. Taunton-Rigby has managed product development from basic research to FDA approval, marketing and sales. Her experience includes: significant strategic, regulatory, sales, reimbursment and international experience. She was awarded the OBE (Officer of the Order of the British Empire) in June 2002 by Her Majesty, Queen Elizabeth II for leadership in the research, development and promotion of biotechnology.
Guillermo Tearney M.D., Ph.D. is Professor of Pathology at Harvard Medical School, an Affiliated Faculty member of the Harvard-MIT Division of Health Sciences and Technology (HST), and the Associate Director of the Wellman Center for Photomedicine at the Massachusetts General Hospital. Dr. Tearney received his MD magna cum laude from Harvard Medical School and received his PhD in Electrical Engineering and Computer Science from the Massachusetts Institute of Technology.
Dr. Tearney’s research interests are focused on the development and clinical validation of non-invasive, high-resolution optical imaging methods for disease diagnosis. Dr. Tearney's lab was the first to perform human imaging in the coronary arteries and gastrointestinal tract in vivo with Optical Coherence Tomography (OCT), which provides cross-sectional images of tissue architectural microstructure at a resolution of 10 μm. He has also conducted many of the seminal studies validating OCT and is considered an expert on OCT image interpretation. Recently, Dr. Tearney's lab has invented a next generation OCT technology, termed μOCT, which has a resolution of 1 μm and is capable of imaging cells and sub cellular structures in the coronary wall. Dr. Tearney has also developed several other technologies, including a confocal endomicroscope capable of imaging the entire esophagus, an ultraminiature three-dimensional endoscope, a highly efficient form of near field scanning optical microscopy (NSOM), and novel fluorescence spectroscopy and multimodality imaging techniques. He has an active program in Raman spectroscopy and has conducted the first intracoronary Raman in vivo. Dr. Tearney is co-editor of The Handbook of Optical Coherence Tomography and has written over 170 peer-reviewed publications, including papers that have been highlighted on the covers of Science, Nature Medicine, Circulation, Gastroenterology, and Journal of American College of Cardiology.
Dr. Tearney’s work extends beyond his laboratory at MGH, many of his technologies are being produced commercially and he has founded the International Working Group on Intracoronary OCT Standardization and Validation, a group that is dedicated to establishing standards to ensure the widespread adoption of this imaging technology.
Dr. David Walt is Robinson Professor of Chemistry, and Howard Hughes Medical Institute Professor at Tufts University. He is a Member of the National Academy of Engineering, a Fellow of the American Institute of Medical and Biological Engineers, a Fellow of the American Association for the Advancement of Science, and is a Panel Member of the Bill and Melinda Gates Foundation's Global Health Diagnostics Working Group. Dr. Walt has published over 200 papers and is named as an inventor or co-inventor of over 40 patents. He also serves as a board member for Quanterix, Inc. Dr. Walt holds a B.S. in Chemistry from the University of Michigan and received his Ph.D. in Chemical Biology from SUNY at Stony Brook.
Phillip D. Zamore is the Gretchen Stone Cook Professor of Biomedical Sciences and an investigator of the Howard Hughes Medical Institute. He received his A.B. (1986) and his Ph.D. (1992) from the Department of Biochemistry and Molecular Biology at Harvard University. After post-doctoral studies at the Massachusetts Institute of Technology, he joined the faculty of the University of Massachusetts Medical School in 1999.
A 2000 Pew Scholar in the Biomedical Sciences and a 2002 W.M. Keck Foundation Young Scholar in Medical Research, he is also an honorary member of Alpha Omega Alpha. Dr. Zamore studies the biochemical mechanisms and biological functions of small silencing RNAs, including those that act in the RNA interference (RNAi) pathway. He is especially interested in the intersection of RNA silencing pathways and animal development and in the application of RNAi as a therapy for human diseases, especially Huntington’s disease.
Dr. Zamore is a co-founder of Alnylam Pharmaceuticals, Inc., a company that seeks to develop RNAi-based therapies for human diseases. He serves on the scientific advisory boards of Alnylam and of Regulus Pharmaceuticals, Inc., a microRNA-therapeutics company.